Eledon Pharmaceuticals
ELDN
48 hedge funds and large institutions have $29.7M invested in Eledon Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 7 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
2% less funds holding
Funds holding: 49 → 48 (-1)
7% less capital invested
Capital invested by funds: $32.1M → $29.7M (-$2.4M)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$1.2M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$272K |
| 3 |
PAM
Paradigm Asset Management
New York
|
+$120K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$88.3K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$73.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.33M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$859K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$429K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$206K |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
-$142K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
RhumbLine Advisers
Boston,
Massachusetts
| – | -$64K | -70 | Closed |
|
52
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$56K | -65 | Closed |
|
|
FMA
53
FNY Managed Accounts
New York
| – | -$36.1K | -40 | Closed |
|
54
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$2.21K | -2 | Closed |
|
55
Wells Fargo
San Francisco,
California
| – | -$2.21K | -2 | Closed |
|
ELDN Hedge Fund Activity: Q2 2016 in Review
48 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2016, worth a combined $29.7M — down 7.5% from $32.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ELDN and 6 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 17 added.
The largest buyer was Perceptive Advisors, adding an estimated $1.2M. The largest seller was Novo Holdings A/S, cutting an estimated $2.33M.
- 48 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2016, down from 49 in Q1 2016.
- Funds reported $29.7M of Eledon Pharmaceuticals stock for Q2 2016, down 7.5% quarter-over-quarter.
- 6 funds opened new Eledon Pharmaceuticals positions in Q2 2016 and 7 closed out, a net change of -1 holder.
- The largest Eledon Pharmaceuticals buyer in Q2 2016 was Perceptive Advisors, an estimated $1.2M added.
- The largest Eledon Pharmaceuticals seller in Q2 2016 was Novo Holdings A/S, an estimated $2.33M sold.
Based on aggregated 13F filings for Q2 2016.